Cue Biopharma
Mobilizing the Patient’s Immune System to Treat Serious Diseases
DESIGNED FOR SELECTIVITY
Our engineered biologics are designed to mimic nature’s signals to selectively expand and activate specific immune cells and restore immune balance.
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
Read press release
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Read press release
View all news
